X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
female (30) 30
male (30) 30
oncology (29) 29
index medicus (28) 28
aged (25) 25
middle aged (25) 25
adult (19) 19
aged, 80 and over (16) 16
sulfonamides - administration & dosage (16) 16
sulfonamides - adverse effects (14) 14
leukemia, lymphocytic, chronic, b-cell - drug therapy (13) 13
treatment outcome (13) 13
administration, oral (12) 12
cancer (12) 12
leukemia (12) 12
antineoplastic agents - adverse effects (11) 11
bridged bicyclo compounds, heterocyclic - administration & dosage (11) 11
analysis (10) 10
chemotherapy (10) 10
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - pharmacokinetics (9) 9
dose-response relationship, drug (9) 9
lymphomas (9) 9
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (9) 9
sulfonamides - pharmacokinetics (9) 9
expression (8) 8
human necessities (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
preparations for medical, dental, or toilet purposes (8) 8
rituximab (8) 8
aniline compounds - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
apoptosis (7) 7
bridged bicyclo compounds, heterocyclic - adverse effects (7) 7
disease-free survival (7) 7
hematology (7) 7
neoplasms - drug therapy (7) 7
open-label (7) 7
pharmacokinetics (7) 7
pharmacology & pharmacy (7) 7
specific therapeutic activity of chemical compounds ormedicinal preparations (7) 7
venetoclax (7) 7
abridged index medicus (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic agents - therapeutic use (6) 6
article (6) 6
bcl-2 (6) 6
care and treatment (6) 6
chemistry (6) 6
cohort studies (6) 6
drug administration schedule (6) 6
heterocyclic compounds (6) 6
metallurgy (6) 6
organic chemistry (6) 6
proteins (6) 6
recurrence (6) 6
therapy (6) 6
time factors (6) 6
aniline compounds - administration & dosage (5) 5
aniline compounds - pharmacokinetics (5) 5
animals (5) 5
area under curve (5) 5
chromosome deletion (5) 5
chronic lymphatic leukemia (5) 5
chronic lymphocytic leukemia (5) 5
chronic lymphocytic-leukemia (5) 5
clinical trials (5) 5
cll (5) 5
fludarabine (5) 5
inhibitor (5) 5
leukemia, lymphocytic, chronic, b-cell - mortality (5) 5
maximum tolerated dose (5) 5
patients (5) 5
research (5) 5
resistance (5) 5
tumors (5) 5
abt-199 (4) 4
acyclic, carbocyclic or heterocyclic compounds containingelements other than carbon, hydrogen, halogen, oxygen, nitrogen,sulfur, selenium or tellurium (4) 4
bridged bicyclo compounds, heterocyclic - pharmacokinetics (4) 4
cancer therapies (4) 4
clonal deletion (4) 4
cyclophosphamide (4) 4
disease progression (4) 4
diseases (4) 4
drug dosages (4) 4
drug resistance, neoplasm (4) 4
hematology, oncology and palliative medicine (4) 4
ibrutinib (4) 4
leukemia, lymphocytic, chronic, b-cell - pathology (4) 4
lymphatic leukemia (4) 4
neutropenia (4) 4
pharmacology/toxicology (4) 4
rabbits (4) 4
relapse (4) 4
ryanodine - analogs & derivatives (4) 4
studies (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 768 - 778
Journal Article
Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. SY24-02 - SY24-02
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 2, pp. 230 - 240
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
An oral inhibitor of BCL2 produces substantial responses in the majority of patients with refractory chronic lymphocytic leukemia. The agent is so effective... 
DOSE-ESCALATION | APOPTOSIS | MEDICINE, GENERAL & INTERNAL | CLL | INTERNATIONAL WORKSHOP | CYCLOPHOSPHAMIDE | RITUXIMAB | IBRUTINIB | INHIBITOR | PHASE-I | FLUDARABINE | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Lymphomas | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 02/2013, Volume 19, Issue 2, pp. 202 - 208
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 216 - 228
Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with... 
INTENSIVE CHEMOTHERAPY | BCL-2 INHIBITION | OLDER PATIENTS | ONCOLOGY | ABT-199 | CARE | Antimitotic agents | Aged patients | Antineoplastic agents | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 488 - 496
Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and... 
APOPTOSIS | LYMPHOMA-CELLS | ANTAGONIST ABT-737 | ONCOLOGY | SENSITIVITY | RESISTANCE | BH3 MIMETIC ABT-737 | CANCER | CHEMOTHERAPY | CELL-DEATH | FAMILY | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Bcl-2-Like Protein 11 | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Aniline Compounds - administration & dosage | Chromosome Deletion | Proto-Oncogene Proteins - metabolism | Aniline Compounds - pharmacology | Drug Administration Schedule | Administration, Oral | In Situ Hybridization, Fluorescence | Treatment Outcome | Thrombocytopenia - chemically induced | Aniline Compounds - pharmacokinetics | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Apoptosis Regulatory Proteins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Myeloid Cell Leukemia Sequence 1 Protein | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Aniline Compounds - adverse effects | Sulfonamides - administration & dosage | Hema7 | ORIGINAL REPORTS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2017, Volume 39, Issue 2, pp. 359 - 367
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 65 - 75
Journal Article
Journal Article